News
Nutrition entrepreneur, Melissa Snover, named in Department for Business & Trade’s inaugural Female Founders Initiative
Award-winning entrepreneur and founder of Birmingham-based Rem3dy Health and Nourished, Melissa Snover, has been named as one of ten winners in the Department for Business & Trade’s (DBT) Venture Capital Unit’s inaugural Female Founders initiative.
The national campaign was launched by the DBT to identify a cohort of ten of the UK’s most promising female-led companies.
An esteemed panel of VC judges comprehensively scored each of the shortlisted companies, with only the most innovative products with great market potential, scalability and commercial viability making it into the first cohort of 10.
At a special launch event taking place today (17 September) in London, Melissa, along with her fellow female founders cohort, delivered one-minute elevator pitches describing their innovative solutions, providing a powerful platform to engage with some of the most prominent stakeholders and investors in the international VC sector.
Innovative women-led start-ups have been notoriously held back due to a lack of finance, with the proportion of equity capital investment going to all-female founder teams sitting at around 2 per cent in the UK for the past decade.
In response to this disparity, the Department for Business and Trade’s Venture Capital Unit launched a national campaign to identify and support the UK’s 10 most promising tech female founders.
Over the coming year, each will be offered opportunities to access the Venture Capital Unit’s global investor network.
Melissa Snover, said: “Recently, investment into female-led businesses has been heavily scrutinised, so today’s launch is significant, not just for me and the other nine female founders in the cohort, but for the entrepreneurial and investment communities as a whole.
“At a time when it’s becoming increasingly difficult to access funding, I’m absolutely delighted to have been selected in the DBT’s first ever Female Founders initiative.
“For over two decades I’ve been passionate about innovation in the field of nutrition and improving lives through science, and my latest company, Nourished, is creating something unique in the market.
“Securing a place on this initiative will give me an invaluable opportunity to showcase the brand and our breakthrough product to a global network of investors, all of whom are actively looking for investment opportunities here in the UK.”
With over 20 years’ entrepreneurial experience, including multiple successful exits, Melissa has established a strong track record for innovation and brand building.
A registered nutritionist and inventor of several patented technologies, in 2019 Melissa founded Rem3dy Health and raised the highest ever female founder seed round in UK history.
Rem3dy Health is dedicated to pioneering personalised health solutions for both preventative and curative care through its brands, Nourished (personalised nutrition) and Scripted (personalised medicine).
The firm was recently honoured with the prestigious King’s Award for Enterprise in Innovation, for its use of patented 3D printing technology and a unique vegan encapsulation formula; both developed inhouse to create authentically personalised nutrition on demand under the brand Nourished.
Nourished is Melissa’s latest creation, and is the world’s first 3D printed personalised gummy stacks.
Diagnosis
Lung cancer drug shows breast cancer potential
Ovarian cancer cells quickly activate survival responses after PARP inhibitor treatment, and a lung cancer drug could help block this, research suggests.
PARP inhibitors are a common treatment for ovarian cancer, particularly in tumours with faulty DNA repair. They stop cancer cells fixing DNA damage, which leads to cell death, but many tumours later stop responding.
Researchers identified a way cancer cells may survive PARP inhibitor treatment from the outset, pointing to a potential way to block that response. A Mayo Clinic team found ovarian cancer cells rapidly switch on a pro-survival programme after exposure to PARP inhibitors. A key driver is FRA1, a transcription factor (a protein that turns genes on and off) that helps cancer cells adapt and avoid death.
The team then tested whether brigatinib, a drug approved for certain lung cancers, could block this response and boost the effect of PARP inhibitors. Brigatinib was chosen because it inhibits multiple signalling pathways involved in cancer cell survival.
In laboratory studies, combining brigatinib with a PARP inhibitor was more effective than either treatment alone. Notably, the effect was seen in cancer cells but not normal cells, suggesting a more targeted approach.
Brigatinib also appeared to act in an unexpected way. Rather than working through the usual DNA repair routes, it shut down two signalling molecules, FAK and EPHA2, that aggressive ovarian cancer cells rely on. FAK and EPHA2 are proteins that relay survival signals inside cells. Blocking both at once weakened the cells’ ability to adapt and resist treatment, making them more vulnerable to PARP inhibitors.
Tumours with higher levels of FAK and EPHA2 responded better to the drug combination. Other data link high levels of these molecules to more aggressive disease, pointing to potential benefit in harder-to-treat cases.
Arun Kanakkanthara, an oncology investigator at Mayo Clinic and a senior author of the study, said: “This work shows that drug resistance does not always emerge slowly over time; cancer cells can activate survival programmes very early after treatment begins.”
John Weroha, a medical oncologist at Mayo Clinic and a senior author of the study, said: “From a clinical perspective, resistance remains one of the biggest challenges in treating ovarian cancer. By combining mechanistic insights from Dr Kanakkanthara’s laboratory with my clinical experience, this preclinical work supports the strategy of targeting resistance early, before it has a chance to take hold. This strategy could improve patient outcomes.”
Insight
Higher nighttime temps linked to increased risk of autism diagnosis in children – study
Entrepreneur
Kindbody unveils next-gen fertility platform
-
Insight4 weeks agoDesigner perfumes recalled over banned chemical posing fertility risk
-
Insight2 weeks agoParents sue IVF clinic after delivering someone else’s baby
-
Insight3 weeks agoWomen’s health could unlock US$100bn by 2030
-
Insight4 weeks agoChina’s birth rate hits record low despite government fertility efforts
-
Menopause3 weeks agoHRT linked to greater weight loss on tirzepatide
-
Entrepreneur6 days agoUS startup builds wearable hormone tracker
-
Menopause2 weeks agoFlo Health and Mayo Clinic publish global perimenopause awareness study
-
News4 weeks agoVerdane invest in Clue to accelerate the future of women’s health







1 Comment